AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06304571
Drug: HC006
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT05364255
Drug: [14C]AZD9833 Oral Solution, 75 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Solution, 75 mg (NMT 0.67 MBq) - oral, fasted
Trial: NCT05332795
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gouty patients, will receive placebo tablets once daily for about 3 months.
Trial: NCT05007444
Drug: P2Et (Caesalpinia spinosa extract)
RxNorm normalized name: Caesalpinia spinosa whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients who meet inclusion criteria will begin taking 4000mg daily, distributed in 2 doses with meals of 2000mg of P2Et extract during neoadjuvant treatment. In case of presenting toxicity, it will be lowered to the next dose level, that is, 2000 mg under the same dosage schedule and 1000 mg following the same principle. The taking of the phytomedicine will only be suspended 3 days before each cycle of standard neoadjuvant therapy and will restart 3 days after having passed the cycle. That is, in the anthracyclines and cyclophosphamide (AC) phase, the patient will start taking the phytomedicine 3 days after having received their standard chemotherapy cycle and will suspend it 3 days after the next cycle begins. For the taxane phase, the patient will take the P2Et without suspension during the treatment cycles.
Trial: NCT05007444
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After determining the optimal biological dose (OBD), the patients will be divided into the placebo arm or the treatment arm. In the anthracyclines and cyclophosphamide (AC) phase, the patient will start taking according to the asignation as stated in the drug intervention.
Trial: NCT05099445
Drug: INCB000928
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INCB000928 200 mg will be administered on Day 1 of each treatment period.
Trial: NCT05456503
Drug: FPI-2620
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiotracer
Trial: NCT04983732
Drug: FL-101-Intravenous
RxNorm normalized name: OXT-101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg administered via the IV route
Trial: NCT04983732
Drug: FL-101-Subcutaneous
RxNorm normalized name: OXT-101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg administered via the SC route
Trial: NCT06217146
Drug: Placebo Oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Oil
Trial: NCT04925934
Drug: VIB7734
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VIB7734
Trial: NCT04828525
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT05320588
Drug: BIO-106
RxNorm normalized name: Bio-Kool
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIO-106 is a novel antibody-drug conjugate (ADC) that targets the human trophoblast cell surface antigen 2 (Trop-2)
Trial: NCT05789342
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Rosuvastatin, tablet, oral
Trial: NCT05099276
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three capsules of cellulose given in post-anesthesia room and three capsules for postop cay one and three capsules for postop day two
Trial: NCT05484167
Drug: Natesto Nasal Product
RxNorm normalized name: Natesto Nasal Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal Gel used for 90 days then crossed over to placebo gel
Trial: NCT05484167
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A nasal gel with no active ingredients
Trial: NCT00232921
Drug: caudal volume 1
RxNorm normalized name: VOLUME EXPANDERS
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT06367114
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide is used for lymphodepletion.
Trial: NCT06488001
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo given the night before surgery, 2 hours prior to surgery, and the evening after surgery.
Trial: NCT05314725
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 days of placebo after surgery
Trial: NCT05570422
Drug: KRC-01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KRC-01 is a solution that contains hydrogen peroxide 3% with sodium hyaluronate 1%. Hydrogen peroxide is the active ingredient for this radiosensitizer.
Trial: NCT04935515
Drug: Intravenous Antibiotics with Low dose steroid.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ceftriaxone with either oral methyl prednisolone or intravenous dexamethasone was given
Trial: NCT00000987
Drug: Doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05673655
Drug: intraoral trigger point injection by botox
RxNorm normalized name: onabotulinumtoxinA Injection [Botox]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intraoral injection of trigger point of masseter muscle by botulinum toxin
Trial: NCT05673655
Drug: transcutaneous trigger point injection by botox
RxNorm normalized name: onabotulinumtoxinA Injection [Botox]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: transcutaneous injection of masseter muscle by botulinum toxin
Trial: NCT05797077
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Maintenance therapy is recommended to be continued with low-toxicity drugs such as 5-FU/LV or capecitabine, and may be combined with targeted therapy. Treatment should be discontinued once ctDNA testing is negative.
Trial: NCT05898373
Drug: vedicitumomab (Edisil, RC48）
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenously for 6-8 cycles before surgery and postoperative radiotherapy, followed by Treatment with injectable recombinant humanized anti-HER2 monoclonal antibody-MMAE coupling agent vedicitumomab (Edisil, RC48) until 1 year or disease progression or intolerable toxicity in locally advanced patients , and until disease progression or intolerable toxicity in metastatic patients .
Trial: NCT06273930
Drug: 8% Arginine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arginine contributes to Whole Mouth Health. It also plays a role with respect to dental caries, helping to maintain a pH-neutral environment, and is proven to rapidly help relieve dentin sensitivity. Arginine is truly a remarkable ingredient now being used in oral care products.
Trial: NCT06591091
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Listed in arm/group description
Trial: NCT05551221
Drug: Ningmitai capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ningmitai Capsule (Ningmitai®) is Traditional Chinese Medicine which has already used in treatment of urinary system disease (eg. CPPS, BPH) in China for more than twenty years. The instruction of Ningmitai Capsule is 0.38g/capsule, 4 capsule/time, tid.
Trial: NCT01344200
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In Phase I twenty (20) children will receive either celecoxib 14 or 7 mg/kg 120-180 minutes prior to lumbar puncture (LP). In Phase II forty-five (45) children will receive celecoxib 14 mg/kg, 7 mg/kg or placebo in one of 5 time intervals, 1-24 hours prior to LP.
Trial: NCT01344200
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In Phase II forty-five (45) children will receive celecoxib 14 mg/kg, 7 mg/kg or placebo in one of 5 time intervals, 1-24 hours prior to LP.
Trial: NCT04964388
Drug: GLP-1 receptor agonist
RxNorm normalized name: GLP-1 receptor agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diabetes medication
Trial: NCT06512233
Drug: LMW Heparin 5000 U/ML-Aspirin 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arm 1
Trial: NCT06512233
Drug: LMW Heparin 5000 U/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arm 2
Trial: NCT05141747
Drug: MRG002
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administrated intravenously
Trial: NCT06063343
Drug: KAND145
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In Part 1 of the study, single ascending doses of KAND145 will be administered; in Part 2 of the study, multiple ascending doses (BID for 8 days) of KAND145 will be administered.
Trial: NCT06063343
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants randomized to the placebo arms will receive placebo at the same dosing frequency as the experimental arms.
Trial: NCT05074147
Drug: Reduction in the duration of antibiotic therapy 3 weeks or 6 weeks
RxNorm normalized name: REDUCTIC ACID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drugs :~* Rifampin (IP an PO) : 10mg/Kg/12h~* Ofloxacin (PO) : 200Mg/8h~* Levofloxacin (PO) : 500mg ot 1g/ twice a day~* Ciprofloxacin : IV : 400mg/8h if Pseud spp ; 400mg/12h for others Gram-negative bacilli strains; PO : 1gr/12h if Pseud spp ; 750mg/12h for others Gram-negative bacilli strains~* Clindamycin : 600-900mg/8h~* Fusidic Acid : 500mg/8h~* Teicoplanin : 10mg/kg/12h for 5 dosis in combination, then in monotherapy.~* Ceftasidim : 2g/8h if Pseud spp ; 2g/12h for others Gram-negative bacilli strains~* Trimethoprim-sulfamethoxazole (800mg/160mg) : once per day if patient \< 80Kg ; one and a half per day if patient \> 80Kg.~* Doxycyclin : 200mg/day~* Minocyclin : 100mg/8h to 12h~* Ceftriaxon : 1g to 2g/day in IV, IM or SC~* Cefotaxim : 1g to 2g/day in IV~* Pristinamycin : 1g thrice a day
Trial: NCT05810623
Drug: Intravesical Solution
RxNorm normalized name: Rimso-50 Intravesical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravesical single dose instillation of chemotherapy within 24h from uretero-renoscopy
Trial: NCT04757584
Drug: Beta blockers
RxNorm normalized name: BETA BLOCKERS/RELATED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The intervention is a two-arm crossover withdrawal/ reversal design (On \[A\] vs Off \[B\]) with up to 4 periods, each period lasting up to 6 weeks. During the On period (A), subjects will be on their beta blocker. During the Off period (B), their beta blockers will be down-titrated and subsequently discontinued.~Subjects will be randomized into either ABAB or BABA sequences.
Trial: NCT04837742
Drug: ESPB group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ESPB injection at T10 region with Chirocaine 100mg(20 cc)+ Omnipaque 10cc
Trial: NCT04837742
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ESPB injection at T10 region with Normal saline 20cc + Omnipaque 10cc
Trial: NCT04656431
Drug: Hyperpolarized pyruvate (13C)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given intravenously (IV) injection prior to imaging
Trial: NCT05125978
Drug: Canadá
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Canadá association 1 tablet twice a day
Trial: NCT04798287
Drug: TNF Inhibitor
RxNorm normalized name: Tumor necrosis factor alpha (TNF-alpha) inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First eligible prescription for treating rheumatoid arthritis (RA)
Trial: NCT05895500
Drug: Tablet (50mg/tablet), oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet
Trial: NCT05901961
Drug: Whitfield solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patient will receive 60 mL of Whitfield solution. They will be instructed to apply 0.5 mL of the solution to the lesion twice daily for a consecutive period of 8 weeks.
Trial: NCT05901961
Drug: Zinc oxide nanoparticles solution
RxNorm normalized name: Zinc Oxide
DrugBank: Zinc oxide (DB09321)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The patient will receive 60 mL of 1% Zinc oxide nanoparticles solution. They will be instructed to apply 0.5 mL of the solution to the lesion twice daily for a consecutive period of 8 weeks.
Trial: NCT05901961
Drug: Combined Whitfield and Zinc oxide nanoparticles solution
RxNorm normalized name: Zinc Oxide
DrugBank: Zinc oxide (DB09321)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The patient will receive 60 mL of combined Whitfield and Zinc oxide nanoparticles solution. They will be instructed to apply 0.5 mL of the solution to the lesion twice daily for a consecutive period of 8 weeks.
Trial: NCT06028737
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 200 mg/m², d1, i.v., every 2 weeks
Trial: NCT06028737
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2600 mg/m²d1 i.v. every 2 weeks
Trial: NCT06134414
Drug: MY008211A tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dose 1 (400 mg BID) and dose 2 (600 mg BID) in a 1:1 ratio by central randomization
Trial: NCT04937530
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Comparator: Placebo Inactive comparator capsule 960 mg/capsule: 3 capsules TID for 4 weeks, followed by 3 capsules BID for the remaining 44 weeks.
Trial: NCT04987970
Drug: D013, D326, D337
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QD, PO
Trial: NCT05082155
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline will be delivered as a basal infusion of 1 mL/h and an automatic intermittent bolus of 20 mL every 4 hours.
Trial: NCT05406895
Drug: 2% Lidocaine with 1:100,000 epinephrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% Lidocaine with 1:100,000 epinephrine will be used for administering the lower jaw anesthesia (inferior alveolar nerve block).
Trial: NCT06193629
Drug: Lang Qingata
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lang Qingata: (Artificial bezoar: 0.1g, Safflower: 15g, five spirit fat: 15g, Tangerine: 30g, Swertia: 15g, nutmeg: 10g, Astragalus: 25g, wood fragrance: 10g, Parasol tiger grass: 15g, Coriander fruit: 10g, Agarwood: 3g, pomegranate seed: 20g, Rhododendron: 8g, Dongquai fruit: 15g, licorice: 10g). Water decoction (hospital decoction), Decoction in water for oral use，2 times/day, 4 weeks for a course of treatment.
Trial: NCT06193629
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is a Chinese medicine granule with 5% active ingredient and has the same taste as Lang Qingata，Decoction in water for oral use
Trial: NCT00629213
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04608851
Drug: E. coli Nissle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 ml of oral suspension containing 10 E8 CFU /ml of E. coli Nissle strain
Trial: NCT06364540
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Nebulized fentanyl administered at 3 mcg/kg via BAN
Trial: NCT05697692
Drug: Heparin sodium
RxNorm normalized name: Heparin Sodium
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lung transplantation on central veno-arterial ECMO with standard additional heparin
Trial: NCT05697692
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lung transplantation on central veno-arterial ECMO without additional heparin
Trial: NCT04808895
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: administration of one tablet daily for 15 days. On the first day a loading dose of 300 mg will be administered
Trial: NCT04808895
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administration of one tablet daily for 15 days. On the first day 3 tablets will be administered
Trial: NCT04773977
Drug: IBI362 liquid formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered by subcutaneous injection
Trial: NCT04773977
Drug: IBI362 lyophilized powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered by subcutaneous injection
Trial: NCT05187832
Drug: AND019 PO QD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AND019 administrated as oral capsule once per day for 28 days for each cycle
Trial: NCT05420454
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 600 mg/m2, d1, q3w ,4 cycles,followed by docetaxel
Trial: NCT05420454
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 600 mg/m2, d1, q2w × 4 cycles followed by nab-paclitaxel
Trial: NCT05673850
Drug: NET or NCT
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In this study, we included 518 ER-positive BC patients who received either neoadjuvant endo-crine therapy (NET) or neoadjuvant chemotherapy (NCT).
Trial: NCT05206331
Drug: Iodinated Contrast Media (ICM)
RxNorm normalized name: Stellaria media extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: standard FDA-approved low osmolarity Iodine contrast agent with 350-370 mg/ml
Trial: NCT04889651
Drug: BR9004
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BR9004: Abiraterone acetate 200mg, Boryung Pharmaceutical Co., Ltd.
Trial: NCT04889651
Drug: BR9004-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BR9004-1: Zytiga Tab. 500mg (Abiraterone acetate 500mg), Janssen Korea
Trial: NCT06358677
Drug: Topical Tretinoin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical tretinoin will be applied to one half of the face, either left or right side. The side the topical tretinoin will be applied to will be randomized.
Trial: NCT06401616
Drug: OAC will be discontinued for the duration of the trial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuation of warfarin, dabigatran, rivaroxaban, apixaban or edoxaban
Trial: NCT05937100
Drug: Biodentine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Molars will be anesthetized by local anesthesia. The rubber dam will be used for isolation. Caries will be removed by large spoon excavator. When pulpal exposure occurs, deroofing of the pulp chamber will be achieved then pulpal tissue will be amputated using sharp excavator. Hemostasis will be obtained by applying pressure with saline moist cotton pellet. If bleeding has not stopped within 5 min, tooth will be excluded from the study.The biodentine mix will be prepared according to the manufacturer's instructions and condensed lightly with a condenser on the pulp stumps
Trial: NCT05552495
Drug: D013, D326, D337
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D013 1 Tablet, D326 1Tablet, D337 1 Tablet
Trial: NCT05525715
Drug: 2mg QY201 tablets or 2mg QY201 placebo,BID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2mg QY201 tablets or 2mg QY201 placebo,BID
Trial: NCT05525715
Drug: 5mg QY201 tablets or 5mg QY201 placebo,BID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5mg QY201 tablets or 5mg QY201 placebo,BID
Trial: NCT05525715
Drug: 10mg QY201 tablets or 10mg QY201 placebo,QD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10mg QY201 tablets or 10mg QY201 placebo,QD
Trial: NCT05525715
Drug: 10mg QY201 tablets or 10mg QY201 placebo,BID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10mg QY201 tablets or 10mg QY201 placebo,BID
Trial: NCT05525715
Drug: 15mg QY201 tablets or 15mg QY201 placebo,BID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15mg QY201 tablets or 15mg QY201 placebo,BID
Trial: NCT05525715
Drug: 20mg QY201 tablets or 20mg QY201 placebo,BID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20mg QY201 tablets or 20mg QY201 placebo,BID
Trial: NCT05525715
Drug: 5mg QY201 tablets，BID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5mg QY201 tablets，BID
Trial: NCT05525715
Drug: 10mg QY201 tablets，BID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10mg QY201 tablets，BID
Trial: NCT05525715
Drug: 20mg QY201 tablets，BID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20mg QY201 tablets，BID
Trial: NCT05525715
Drug: QY201 placebo，BID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QY201placebo，BID
Trial: NCT04728581
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a gelatinous capsule without an active ingredient
Trial: NCT05195827
Drug: PRM-125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihypertensive
Trial: NCT05013567
Drug: Ibuprofen gel
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen gel 5% topically four times a day
Trial: NCT05733533
Drug: Matching placebo to HRS-2261
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo to HRS-2261, oral, BID
Trial: NCT04862845
Drug: sham
RxNorm normalized name: SHAMPOO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: received two placebo capsules at 90 minutes preoperatively then placebo capsules every 12 hours, with one capsule daily postoperatively until the fifth postoperative day.
Trial: NCT01970111
Drug: KPS-0373, High dose
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01970111
Drug: KPS-0373, Low dose
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05508594
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal
Trial: NCT05508594
Drug: Sufentanil
RxNorm normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal
Trial: NCT04806945
Drug: Placebo to HLX10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion
Trial: NCT05697003
Drug: ADVAIR DISKUS 100/50
RxNorm normalized name: Advair Diskus 100/50 Dry Powder Inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 inhalations in one study period
Trial: NCT04867603
Drug: [Ga-68]PSMA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The injectable activity will be a maximum of 210 MBq (6.0 mCi) \[Ga-68\]PSMA at the time of injection and is administered to subjects by intravenous injection.